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Summary: Although STI clinics have been the most frequent test setting for men and outpatient 
clinics for women, emergency departments are increasingly a source of testing and morbidity.    
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ABSTRACT 
Background:  Despite major efforts to control their spread, reported sexually transmitted 
infections (STI) are increasing. Using data from a mid-sized Midwest metropolitan area, we 
examined the settings in which individuals are tested for gonorrhea and chlamydia in relation to 
demographics and test result to determine where interventions may best be focused.  
Methods:  A de-identified and integrated registry, containing records from all patients tested for 
an STI from 2003-2014, was created by combining data from a large health information 
exchange and the reporting district’s STI Program located in Indianapolis, IN.  Individual 
characteristics and visit settings where gonorrhea and chlamydia testing was performed were 
analyzed.   
Results:  We identified 298,946 individuals with 1,062,369 visits where testing occurred at least 
once between the ages of 13 and 44 years.  Females were tested significantly more often than 
males and received testing more often in outpatient clinics whereas males were most often tested 
in the STI clinic.  Individuals who utilized both STI and non-STI settings were more likely to 
have a positive test at an STI or ED visit (6.4% - 20.8%) than outpatient or inpatient setting (0.0-
11.3%) (p<.0001). Test visits increased over the study period particularly in emergency 
departments, which showed a substantial increase in the number of positive test visits. 
Conclusions:  The most frequent testing sites remain STI clinics for men and outpatient clinics 
for women. Yet, emergency departments are increasingly a source of testing and morbidity. This 
makes them a valuable target for public health interventions that could improve care and 
population health. 
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INTRODUCTION 
Chlamydia and gonorrhea remain the first and second most frequent notifiable infectious 
diseases in the United States together numbering more than 2 million cases annually (1) at a 
lifetime cost of over $650 million (2) and a loss of productivity greater than the cost of care for 
working individuals (3).  However, despite all efforts, gonorrhea and chlamydia are still 
increasing (1) mandating development of alternative approaches.  In the absence of vaccines, this 
means enforcing best practices for STI control and prevention.  In addition to the 
recommendation to screen all sexual women aged <25 years, STI control in the US relies on 
local STI programs and associated STI clinics to diagnose, verify treatment and perform contact 
tracing.  Increasingly however, STIs are diagnosed outside of publicly funded STI clinics.  For 
example, in 2015, public STI clinics diagnosed 7% of chlamydial infections, 12% of gonorrhea 
and 20% of primary and secondary syphilis compared to 2003 when STI clinics reported 18%, 
30% and 40% of chlamydia, gonorrhea, and primary and secondary syphilis, respectively (1, 4).  
Although STI clinics in larger cities may diagnose a higher proportion of STIs (5), this decrease 
in the proportion of STI morbidity reported by STI clinics mandates evaluation of circumstances 
of testing.  If individuals are going elsewhere for STI services, how should STI programs support 
best practices outside of the STI clinic, such as high-quality rapid testing, partner notification and 
evidenced-based behavioral interventions?  Although prior studies of STI services have 
examined subpopulations, including STI clinic patients, women, Medicaid and large health 
maintenance organization populations, less is known about the general population regarding 
where individuals go for STI related services (6-16).   
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According to the 2016 CDC Surveillance report, Indianapolis ranked 6
th
 in the rate of both 
gonorrhea and chlamydia among selected metropolitan statistical areas (MSAs) in 2016, but 34
th
 
in population
1
.   This national method of ranking is based on the number of reported 
cases/100,000 population but is influenced by reporting completeness, levels of screening, and 
population growth.  The population of the Indianapolis-Carmel-Anderson MSA, which 
encompasses most of central Indiana, for example, increased 29% from 1,525,104 in 2000, to 
1,971,060 in 2014 (US Census). 
The medical record systems of the Indianapolis-Carmel-Anderson MSA have been linked to one 
another through the Indiana Network for Patient Care (INPC), the largest inter-organizational 
clinical data repository in the US.  We examined chlamydia and gonorrhea testing over an eleven-
year period using a comprehensive STI testing registry derived by combining information the INPC 
and the Central Indiana (Indiana District 5) STI program to determine the settings where individuals 
were tested, and the settings associated with the highest rate and absolute number of infections. Our 
goal was to optimize targeting of public health interventions.     
METHODS 
Data Source   
Data from all individuals, ages 13 years and older, who had a chlamydia, gonorrhea, or syphilis 
test performed between January 1, 2003 and December 31, 2014 were extracted from the INPC, 
operated by the Indiana Health Information Exchange (17).  These data were combined with data 
from individuals similarly tested by the Marion County Public Health Department’s (MCPHD) 
STI Program.  Extracted data were integrated into a comprehensive metropolitan STI registry 
(18).  The INPC encompasses all major healthcare systems and laboratories in Central Indiana, 
                                                          
1
 US Census 2010:  2016 estimates: 
https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=bkmk 
https://www.census.gov/data/tables/time-series/dec/c2010sr-01.html Chapter 2 data 
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except for the Veterans Administration. The MCPHD STI Program tests individuals at a full time 
public STI clinic and through several outreach programs in Indiana District 5 (roughly equivalent 
to the Indianapolis-Carmel-Anderson MSA).  The resulting registry contains test information for 
chlamydia, gonorrhea, syphilis, HIV and pregnancy tests, visit information including type of 
clinic (i.e. Emergency Department (ED), outpatient, inpatient, or STI program), visit date 
(transformed relative to the patient’s initial visit), visit year, diagnostic codes, infection status at 
time of visit and demographics including age, gender, race, and ethnicity.  For this study, 
individuals with any gonorrhea or chlamydia test in the registry between the ages of 13 and 44 
were examined.  Syphilis was excluded from the current study because of the complexity of 
analysis associated with diagnosis and follow up testing.  We analyzed individuals and visits 
rather than tests to control for tests performed at multiple anatomical sites at the same visit on a 
single individual.  Individuals with a positive test at any anatomic site and visits associated with 
a positive test (regardless of anatomic site) were considered positive. Analyses of test visits and 
positivity over time were analyzed from 2005, when the use of nucleic acid amplification tests 
for both gonorrhea and chlamydia were standard across different settings.   Some healthcare 
systems provided data that included the actual clinic site of testing (i.e. OB/GYN, Primary Care, 
etc.), specific visit location information was available on a subset of patients including 63.3% of 
females and 81.2% of males.  These data are provided to give additional information about the 
type of outpatient clinics used for testing.   
 
Matching Algorithm 
Individuals were identified as matches in the two source datasets, the INPC and MCPHD STI 
program, using two probabilistic utilities.  Both utilities use a value-based weight scaling 
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modification of matching based on first, last, and middle names; social security numbers, date of 
birth, race, and gender (19, 20). Global Match is used as a standard in the INPC to match 
individuals from different medical record systems and assigns a unique identifier to matches.  
RecMatch was used to identify matches in the combined MCPHD STI program and INPC data 
(21).  Program-generated matches below the threshold score from RecMatch were excluded.  
Records at or above the threshold score were reviewed manually and a score was chosen where 
no clearcut mismatches were seen in 100 records.    Individuals who matched the 9 digits of the 
social security number alone, for example, if they were given the default social security number 
of 999-99-9999 were excluded (6.3%). Of the 94,055 individuals who had at least one STI test in 
the MCPHD STI dataset, 73.6% matched one of the 449,371 individuals in the INPC dataset. 
These record pairs were merged.    
Statistics 
Descriptive statistics were performed to determine patient characteristics associated with 
presenting to a specific testing setting. Hispanic origin was recorded as race in the INPC but as 
ethnicity in the MCPHD data, with race usually designated as “other”.  For this reason, Hispanic 
and other race were combined for the analysis.  According to the US Census, only 3.9% of 
Indianapolis residents were not white, black or Hispanic so it is likely the majority of “other” is 
equal to Hispanic.  Characteristics of individuals presenting to various testing settings were 
analyzed using mean and standard deviation for continuous variables (age and average number 
of visits/year), and frequency or proportion for categorical variables. Comparisons among the 
testing settings were performed using ANOVA for continuous variables and Pearson    test for 
categorical variables. Characteristics of patients associated with a positive gonorrhea or 
chlamydia test by setting were stratified by gender and were presented using mean and standard 
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deviation for continuous variables, and frequency and proportion for categorical variables. The 
association between patient characteristics and test setting site was evaluated by multinomial 
logistic regression using the generalized logit link, where the test setting site is the response 
variable with STI clinic as the reference. In the model, there are 4 levels (ED, inpatient, 
outpatient and STI clinic) in the response variable. The grouping age (13-29 and ≥30), gender 
and race are the predictor variables in the model, where the interaction of gender and race was 
included in the model to evaluate the association between the testing sites and the race in female 
and male, respectively. The patient effect among the testing sites was also accounted for in the 
model.  All statistical analyses were performed using SAS version 9.4 (SAS Institute Cary, NC).  
The study received approval by the Institutional Review Board at Indiana University (Study No. 
1311659626). 
RESULTS 
From the 474,201 individuals in the combined data, we identified 298,946 unique individuals, 
ages 13 to 44 years, who had at least one test for gonorrhea or chlamydia (referred to as an STI 
test) and at least one visit with encounter information in the combined dataset. These individuals 
had 1,062,369 visit records associated with STI testing.  Most were female (79%).  Forty-three 
percent were white, 39% black and 14% other race.   
Table 1 illustrates the first-visit demographics of the cohort according to whether they received 
testing only in non-STI clinic settings, such as outpatient clinics or an ED; only at the STI clinic; 
or both settings.  Most individuals, 238,251 (79.7%), were tested only in non-STI settings and 
36,397 (12.2%) were tested only in the STI clinic.  A small proportion of individuals, 24,298 
(8.1%), utilized both non-STI and STI settings.  These individuals were significantly younger 
than those who attended non-STI settings or the STI clinic exclusively.   
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Males and females differed in their utilization of different settings for STI testing (p<0.0001). 
Females were more likely to go to only non-STI sites (89.2%) than only STI sites (3.6%) 
(p<.0001) for testing.  Males were slightly more likely to go to only non-STI sites (44.7%) than 
only STI sites (43.6%) (p=0.0049).   
All races were tested most frequently in non-STI settings.  Among those that utilized both STI 
and non-STI settings, 69.5% were black, 21.6% were white and 9% were of other or unknown 
race, roughly similar to the racial breakdown for gonorrhea in 2014 but disproportionate to the 
racial breakdown of the city of  Indianapolis estimated for 2014 from the US Census which was 
62% white, 28% black:  The average number of visits per year was highest (2.0) among those 
who utilized both STI and non-STI settings for their testing, compared with 1.7 for non-STI 
settings only versus 1.2 for STI settings only (both p<.0001). 
The STI clinic and some healthcare systems provided specific patient visit location information 
accounting for 63.3% of female and 81.2% of male visits.  In addition to the STI clinic, 
identified clinics included OB-GYN, primary care, and specialty care such as urology or 
infectious disease.  In this subset, OB-GYN clinics accounted for 37.4% of female visits 
associated with STI testing, EDs, 27.4%, and primary care, 16.3% (p<.0001).  In contrast, most 
males were tested in the STI clinic (61.7%) or the ED (19.1%). Outpatient clinics with the most 
male test visits were primary care (7.6%) and OB-GYN clinics (5.6%). 
Table 2 summarizes patient characteristics for visits associated with STI testing and the 
percentage of visits with positive tests in each setting.  Females were more likely than males to 
have STI test visits in all settings except the STI clinic.  In addition, to gender, the setting in 
which individuals were tested also differed by race.   Relative to the STI clinic, white females 
were more likely to test in the ED, inpatient setting and outpatient settings than black females.  
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Similarly, compared to black males, white males were more likely to test in the ED and inpatient 
settings.  Regardless of race, visits to the ED and the STI clinic had the highest positivity rates 
for both males and females, whereas outpatient and inpatient positivity rates were relatively low. 
Additionally, male positivity rate was higher than that for females in all settings.  
To determine whether test result differed by setting among individuals with visits to both STI 
and non-STI settings, we examined the distribution of 203,170 visits and percent positivity of 
visits among 16,816 females and 7,482 males who had at least one visit to the STI clinic and at 
least one visit to a non-STI setting.  As seen in analyses of the unselected group, the outpatient 
test setting was most common for all ages and females, whereas the STI clinic was the most 
common test setting among males.  Like the unselected group, the percent positivity was highest 
in the ED and STI clinic settings.  For females, the percent positivity was 11.5% and 14.1% for 
chlamydia and 6.4% and 7.9% for gonorrhea in the ED and the STI clinic respectively compared 
to 9.3% for chlamydia and 3.8% for gonorrhea in the outpatient setting. For males, the percent 
positivity was 17.5% and 17.3% for chlamydia and 19.1% and 12.6% for gonorrhea, in the ED 
and the STI clinic respectively compared to 15.6% for chlamydia and 10.4% for gonorrhea in 
outpatient setting. For those 13-29 years, the percent positivity was 14.5% and 18.7% for 
chlamydia and 9.4% and 11.3% for gonorrhea in the ED and STI clinic respectively compared to 
11.6% for chlamydia and 5.0% for gonorrhea in the outpatient setting. 
Figure 1 shows the total number of visits and distribution of total positive test visits associated 
with STI testing in the outpatient, ED and STI clinic settings from 2005 to 2014 for females and 
males.  During this period, the total number of test visits increased from 86,534 to 119,149 for 
females and from 10,297 to 20,727 for males.  Increases occurred in most but not all individual 
institutions including the STI clinic (data not shown).  Female test visits were most frequent in 
AC
CE
PT
ED
11 
 
the outpatient setting followed by the ED.  The outpatient setting contributed the highest 
proportion of positive test visits for females, but this contribution decreased over time.  In 
contrast, the contribution of positive test visits by the ED increased.  STI clinic test visits 
remained relatively low for females during the study period.    
The STI clinic was the most common visit setting for testing for males until 2014 when the 
outpatient setting surpassed it. Although the proportion of visits associated with a positive test 
decreased for the STI clinic throughout the study period, it remained the major source of STI 
morbidity for gonorrhea and chlamydia.  In contrast, however, the ED became the second most 
common source of morbidity for males beginning in 2008 despite the increase in testing in 
outpatient settings.  Inclusion of additional sites to the database did not account for the increase 
in the number of STI test visits across all sites.   
DISCUSSION 
This study is unique in its examination of testing across a wide variety of providers including the 
public health department’s STI clinic.  Creation of the STI registry from a large health 
information exchange and the public STI program was possible only because of collaboration 
across the disciplines of epidemiology, informatics, infectious diseases, and biostatistics (18, 22).   
Systematically captured, integrated, and normalized data available from multiple settings 
allowed for a more complete assessment of where individuals received chlamydia and gonorrhea 
testing and setting-specific positivity rates. Based on our knowledge, this type of assessment at 
the national level is limited, because the availability of existing data sources and the challenging 
management of data across multiple data sources. 
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The resulting data show that the total number of visits associated with gonorrhea and chlamydia 
testing increased significantly during the study period, particularly after 2007.  The increase was 
seen in all test settings and within individual institutions.  The change was greater than the 
increase in the region’s population.  Therefore, the explanation for increased test visits is likely 
to be multifactorial including the increased adoption of urine and self-administered vaginal 
swabs for testing.  The increased availability of STI testing in outpatient settings provides 
opportunities for interventions for both men and women, such as offering PrEP to HIV negative 
young men who have sex with men.   
Gender was a powerful determinant of where individuals were diagnosed with an STI.  
Consistent with surveillance reports (1) our data show the number of females with positive tests 
(morbidity) was greatest from non-STI settings, particularly in outpatient clinics, although the 
positivity rate was lowest in those settings. This is not surprising given the recommended testing 
guidelines for chlamydia and gonorrhea in pregnant women and women aged ≤ 24 years (23).  In 
contrast, the settings with the highest positivity rate were the STI clinic and ED for both females 
and males.  The STI clinic contributed most to male STI morbidity as noted previously (7) but its 
contribution to morbidity is decreasing.  In contrast, EDs are contributing increasingly to 
morbidity, in agreement with the observations of others (12, 13, 16, 24).   Even among 
individuals in our cohort who utilized both STI and non-STI settings, visits to the STI clinic or 
ED, were more likely when there was a positive test consistent with the hypothesis that even if a 
patient has access to an outpatient setting, they utilize settings in which they can obtain 
immediate services for symptoms or suspected exposures.  The registry does not include fields 
derived from text notes which might demonstrate this type of association.  Therefore, whether 
increased ED visits for STI testing is related to access to immediate care, increased geographic 
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distribution of ED relative to STI clinics, decreased stigma (when visiting a location not 
dedicated to STI care) or public health services infrastructure (24) requires further investigation.   
ED-based STI care may not include the comprehensive services critical to STI control (6).  
Optimally restructuring local STI control programs to support STI care in EDs where cost may 
be higher (25) needs further study.  Deployment of existing resources to support EDs such as a 
trained STI clinician in a non-acute area of the ED, assigning DIS for onsite interviews and 
providing ED testing results might prove to be cost effective.   As changes in healthcare unfold, 
the impact of healthcare coverage is likely to change the distribution of sites as well (26).  For 
this study, changes associated with the Affordable Care Act are unlikely to have played a role in 
where individuals went for STI care as Indiana’s plan for expanded Medicaid was approved on 
1/27/2015.
2
  Future updates to the Registry may reveal changes in testing behavior as a result.   
Although younger individuals were more likely to be tested in the outpatient setting or ED, the 
effect was small possibly because the outpatient settings where individuals accessed care was not 
known.  For example, adolescents may have been tested at specialized adolescent or Family 
Planning clinics.  
There are several limitations to note. First, the study was retrospective involving secondary data 
derived from electronic health records. Data was missing or incomplete particularly in types of 
outpatient clinics where chlamydia or gonorrhea tests occurred. While virtually all large 
healthcare and laboratory systems in central Indiana are included in the testing dataset, some are 
not.  These include a small number of non-STI clinics whose tests are performed by the public 
health laboratory.  These gonorrhea and chlamydia tests have only recently been added to the 
INPC.  Individuals who chose to test online or mail-in tests that went to other states were not 
                                                          
2
 https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-
Topics/Waivers/1115/downloads/in/Healthy-Indiana-Plan-2/in-healthy-indiana-plan-support-20-appvl-
01272015.pdf 
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captured.   Second, because different medical record systems used different unique identification 
numbers, the public health and private health system data had to be matched using probabilistic 
techniques.  It is possible but unlikely that data from matched individuals who were truly 
different were merged.  If this were to be the case, the impact on our findings would likely be 
small.    
In conclusion, morbidity reports based only on number of cases must be interpreted with caution 
because of substantial increases in testing over the past decade.  This study provides an important 
and feasible approach to assess time trends of where individuals received STI testing across 
multiple settings, and of setting-specific positivity.  The results from this study provided useful 
information for local STI control and prevention.  Additionally, these findings may be useful for 
other public health and medical communities in the United States.  While STI clinics remain 
critical for the diagnosis of gonorrhea and chlamydial infections, especially in males, visits to the 
ED are increasing not only in number, but also in their rate of positivity presenting a unique 
opportunity to intervene in disease transmission. 
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Figure Legends 
Figure 1:  Distribution of the total number of visits and proportion of positive visits by setting 
from 2005-2014   
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Figure 1 
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Table 1. Patient Characteristics by Testing Setting:  Non-STI vs. STI vs. Both 
 
Table 1: In this Table, patient age is that at first visit by site.  In the case of the Both category, the age at 
first visit to any site was recorded.  Comparisons among the testing settings were performed using 
ANOVA for continuous variables and Pearson    test for categorical variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics Subgroup 
Total 
(298,946) 
Non-STI 
(N=238,251) 
STI 
(N=36,397) 
Both 
(N=24,298) 
p-value 
Age Mean(SD)  26.03+7.47 26±7 28±7 24±7 <.0001 
Gender 
Female 235,163 209,767(89.2%) 8,580(3.6%) 16,816(7.2%) 
<.0001 
Male 63,783 28,484(44.7%) 27,817(43.6%) 7,482(11.7%) 
Race 
Black 115,448 81,414(34.2%) 17,151(47.1%) 16,883(69.5%) 
<.0001 
Other 41,688 37,409(15.7%) 2,584(7.1%) 1,695(7%) 
Unknown 13,810 12,483(5.2%) 852(2.3%) 475(2%) 
White 128,000 106,945(44.9%) 15,810(43.4%) 5,245(21.6%) 
Average 
number of 
visits/year  
Mean+SD 
 1.68+1.37 1.66±1.35 1.23±0.56 2.00±1.70 <.0001 
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Table 2. Multinomial logistic regression of Visit Setting with a Positive STI Test (Gonorrhea and/or 
Chlamydia)  in relation to Age, Gender, and Race by Gender 
 
  ED Outpatient 
STI Clinic 
(reference) 
Characteristic  N 
Positivity 
(%) 
OR  
(95% CI) 
N 
Positivity 
(%) 
OR  
(95% CI) 
N 
Positivity 
(%) 
Age 
13-29 
years 
183,407 15.9% 
1.43 
(1.39,1.48) 
472,485 10.0% 
1.2 
(1.17,1.24) 
78,169 25.90% 
≥30 years 62,135 7.4% reference 191,289 3.4% reference 40,361 14.20% 
Gender 
 
Female 218,506 12.4% 
10.01 
(9.54,10.52) 
620,965 7.8% 
19.55 
(18.59,20.57) 
45,814 18.4% 
Male 27,036 24.8% reference  42,809 13.4% reference  72,716 24.1% 
Race:  Female 
 
Black 100,952 15.5% 
0.57 
(0.55,0.59) 
333,249 10.2% 
0.96 
(0.93,1.00) 
27,627 19.4% 
Other 25,314 10.5% 
1.13 
(1.06,1.22) 
85,343 4.8% 
1.95 
(1.82,2.08) 
3,509 18.2% 
Unknown 5,383 11.6% 
0.79 
(0.71,0.88) 
32,230 4.2% 
2.39 
(2.16,2.64) 
1,093 16.2% 
White 86,857 9.4% reference  170,143 5.2% reference  13,585 16.6% 
Race: Male 
Black 13,916 31.2% 
0.7 
(0.67,0.74) 
24,071 17.4% 
1.05 
(1.00,1.1) 
72,716 28.3% 
Other 2,452 20.9% 
1.35 
(1.24,1.47) 
4,706 8.9% 
2.24 
(2.05,2.45) 
45,665 (19.4%) 
Unknown 1,389 28.1% 
2.43 
(2.14,2.76) 
3,280 6.5% 
4.96 
(4.30,5.71) 
4,200 25.6% 
White 9,279 15.7% reference  10,752 8.4% reference  1,323 16.1% 
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Table 2:  All patient visits were included in this table.  Positivity percentage included positive tests for 
gonorrhea and/or chlamydia. The STI clinic was used as the reference setting for each subgroup. 
Individuals > 30 years were used as a reference when comparing test setting by age.  Males were used as 
the reference when comparing the test setting between genders.  White race was used as the reference 
when comparing the setting between races within gender.  This analysis allows odds ratios (ORs) to be 
compared across 2 variables (e.g. setting and age).  For example, individuals 13-29 were 1.43 times as 
likely to receive a test in the ED as older individuals were to receive a test at the STI clinic.  Also, a larger 
proportion of individuals receiving tests in the ED were 13-29 years than the outpatient setting or STI 
clinic. Inpatient visits are not shown because the number of tests done in this setting was small.  
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